Drug Trial Radar · NCT07198074
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
255
Planned (sponsor's estimate)
Start
Jan 27, 2026
Primary completion
Jul 1, 2028
Study completion Jul 1, 2028
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Sep 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial compares the effect of bevacizumab in combination with carboplatin, paclitaxel and pembrolizumab to the usual treatments of carboplatin and paclitaxel with or without pembrolizumab in treating patients with stage III, IVA or IVB mismatch repair protein proficient (pMMR) and TP53 mutated endometrial cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has come back after a period of improvement (recurrent). Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Adding bevacizumab to the combination of carboplatin, paclitaxel and pembrolizumab may be more effective than the usual treatment combinations of carboplatin and paclitaxel with or without pembrolizumab in treating patients with advanced or recurrent pMMR and TP53 mutated endometrial cancer.
Conditions
- Advanced Endometrial Carcinoma
- Recurrent Endometrial Carcinoma
Interventions
BevacizumabBiological
Given IV
Biospecimen CollectionProcedure
Undergo urine and blood sample collection
CarboplatinDrug
Given IV
Computed TomographyProcedure
Undergo CT
Magnetic Resonance ImagingProcedure
Undergo MRI
PaclitaxelDrug
Given IV
PembrolizumabBiological
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: From study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed up to 5 years
Locations
311 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama · Recruiting
Alaska Women's Cancer Care
Anchorage, Alaska · Recruiting
Cancer Center at Saint Joseph's
Phoenix, Arizona · Recruiting
Banner University Medical Center - Tucson
Tucson, Arizona · Recruiting
University of Arizona Cancer Center-North Campus
Tucson, Arizona · Recruiting
Highlands Oncology Group - Fayetteville
Fayetteville, Arkansas · Recruiting
University of Arkansas for Medical Sciences
Little Rock, Arkansas · Recruiting
Highlands Oncology Group - Rogers
Rogers, Arkansas · Recruiting
Highlands Oncology Group
Springdale, Arkansas · Recruiting
Mercy Cancer Center - Carmichael
Carmichael, California · Recruiting
Mercy San Juan Medical Center
Carmichael, California · Recruiting
Kaiser Permanente Dublin
Dublin, California · Recruiting
Mercy Cancer Center - Elk Grove
Elk Grove, California · Recruiting
Kaiser Permanente-Fremont
Fremont, California · Recruiting
Kaiser Permanente Fresno Orchard Plaza
Fresno, California · Recruiting
Los Angeles General Medical Center
Los Angeles, California · Recruiting
USC / Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
Cedars-Sinai Medical Center
Los Angeles, California · Recruiting
Kaiser Permanente- Modesto MOB II
Modesto, California · Recruiting
Kaiser Permanente-Oakland
Oakland, California · Recruiting
Stanford Cancer Institute Palo Alto
Palo Alto, California · Recruiting
Eisenhower Medical Center
Rancho Mirage, California · Recruiting
Mercy Cancer Center - Rocklin
Rocklin, California · Recruiting
Kaiser Permanente-Roseville
Roseville, California · Recruiting
Kaiser Permanente Downtown Commons
Sacramento, California · Recruiting
Mercy Cancer Center - Sacramento
Sacramento, California · Recruiting
University of California Davis Comprehensive Cancer Center
Sacramento, California · Recruiting
Kaiser Permanente-South Sacramento
Sacramento, California · Recruiting
Kaiser Permanente-San Francisco
San Francisco, California · Recruiting
Kaiser Permanente-Santa Teresa-San Jose
San Jose, California · Recruiting
Kaiser Permanente San Leandro
San Leandro, California · Recruiting
Kaiser San Rafael-Gallinas
San Rafael, California · Recruiting
Kaiser Permanente Medical Center - Santa Clara
Santa Clara, California · Recruiting
Kaiser Permanente-Santa Rosa
Santa Rosa, California · Recruiting
Kaiser Permanente-South San Francisco
South San Francisco, California · Recruiting
Kaiser Permanente-Vallejo
Vallejo, California · Recruiting
Kaiser Permanente-Walnut Creek
Walnut Creek, California · Recruiting
Woodland Memorial Hospital
Woodland, California · Recruiting
UCHealth University of Colorado Hospital
Aurora, Colorado · Recruiting
UCHealth Memorial Hospital Central
Colorado Springs, Colorado · Recruiting
Showing 40 of 311 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.